Health Care & Life Sciences » Pharmaceuticals | Nabriva Therapeutics AG

Nabriva Therapeutics AG

Nabriva Therapeutics AG ADR
Stock Exchange NASDAQ Stock Market
EPS
$2.1
Market Cap
$176.86 M
Shares Outstanding
72.78 M
Public Float
45.37 M

Profile

Address
Leberstrasse 20
Vienna Wien (Vienna) 1110
Austria
Employees -
Website http://www.nabriva.com
Updated 07/08/2019
Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic available for systemic administration in humans. It develops intravenous and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia and intends to develop lefamulin for additional indications other than pneumonia.

Financials

View All

Carrie L. Bourdow
Director
Thomas Lembck
Chief Information Officer